Database→Matrixyl

Tier 2-3SkinAnti-agingPREMIUM

Matrixyl

Matrixyl (Palmitoyl Pentapeptide-4 / Pal-KTTKS); Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7)

Cosmetic ingredient only. Regulated in the USA by FDA as a cosmetic, not a drug. No drug approval exists or has been sought. Reviewed as safe by the Cosmetic Ingredient Review (CIR) Expert Panel. Not a scheduled or controlled substance. Not WADA-listed. No compounding restrictions apply as it is not used as an injectable drug.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) is a synthetic lipopeptide cosmetic ingredient developed by Sederma (France) that mimics matrikine signaling to stimulate collagen synthesis in dermal fibroblasts. The largest clinical trial (Robinson 2005, n=93, 12 weeks, split-face RCT) showed statistically significant wrinkle reduction versus placebo moisturizer. All significant clinical trials were industry-funded. No independently funded academic replication exists. Matrixyl 3000 (a second-generation combination of Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7) extends the mechanism to include anti-inflammatory signaling. No injectable or systemic formulation exists or has been studied.

🔒

Full Profile: Premium Members Only

The complete Matrixyl profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use